Valor Management 13F Portfolio

The one unmistakable conviction statement is Harmony Biosciences. Valor lifts Harmony by +598.4% in share count, adding about $25.5M and turning a $4.3M stub into a $29.8M line. That is not portfolio drift; it is the moment when a name graduates from watchlist to genuine bet.

Harmony sits squarely in neuroscience pharmaceuticals, and Valor is buying it at a gain: current marks are about +17.0% versus the fund’s average cost. They are not averaging down in pain; they are averaging up into apparent validation of the clinical and commercial story.

Viewed alongside Brainsway — a neuromodulation device maker worth roughly $82.4M in the book and up over +201.1% versus average cost — the Harmony add looks like a thematic call. Valor wants exposure to underfollowed, highly specialized CNS therapies and tools where binary clinical catalysts, not macro, drive value.

BIOAGE Labs, though tiny at about $0.3M and down roughly -48.5% versus cost, rounds out this tilt toward biology-of-aging and advanced therapeutics. The fact that Valor is not adding there, while expanding Harmony, suggests a clear relative ranking: late-stage, revenue-generating neuroscience over earlier, longer-duration aging bets.

On the sell side, 13F data shows no large trims by dollars among the top disclosed names, but the absence of buying is telling. Finance exposure — essentially BitGo in this slice of the book — shrinks in weight as health care grows, with no offsetting fresh capital flowing into financial names.

BitGo, at about $65.0M and sitting roughly -32.8% versus Valor’s average cost, is frozen in place: no added shares, no visible reduction. Letting it drift down in portfolio importance without new money implies a thesis they are not ready to abandon yet, but no longer want to emphasize relative to higher-conviction science.

BIOAGE Labs is similarly untouched despite being deeply underwater. Valor’s choice not to scale it, while aggressively scaling Harmony, reads as a quiet downgrade: they will keep optionality, but incremental risk budget is going to nearer-term, derisked neuroscience economics rather than long-tailed discovery platforms.

The sector bar chart will show what the individual trades already imply: health care is becoming the structural anchor of this book. Reported health-care names move from 57.26% to 63.41% of exposure, led in practice by Brainsway, Harmony, and BIOAGE.

The corresponding decline in finance from 42.74% to 36.59% is effectively a relative trim, even in the absence of explicit selling. As Harmony’s stake swells and health-care winners appreciate, BitGo’s slice naturally compresses.

What matters is not just the labels, but the kinds of risks Valor is concentrating into. All of the health-care capital here sits in high-variance, catalyst-driven niches: neuromodulation devices, CNS drugs, and aging biology. Finance exposure, by contrast, is focused on a single crypto-adjacent infrastructure play, suggesting Valor now sees more asymmetry in regulated, IP-protected biology than in the next leg of digital-asset adoption.

Across a difficult quarter — the disclosed book was down -14.29% — Valor’s behavior is the opposite of de-risking. They are choosing to increase concentration in volatile, binary-outcome names where fundamental progress is lumpy but payoff profiles can be extreme.

The decision to scale Harmony at a gain, sit patiently on a more-than-tripled Brainsway, and accept large unrealized losses in BitGo and BIOAGE reveals a consistent playbook: own small, idiosyncratic franchises with non-consensus optionality, and avoid over-trading around mark-to-market noise.

Investors watching Valor should expect future moves to rhyme with this quarter: incremental capital directed toward late-stage, cash-generating health-care platforms with clear clinical catalysts, and a gradually diminishing emphasis on financial experiments that have not delivered. If the science works, this portfolio will not just recover from a single bad quarter — it will look radically different from broad equity benchmarks, by design.